FACULTY CHAIR
Sara A. Hurvitz, MD, FACP
Professor and Head
Division of Hematology/Oncology
UW Medicine
Professor and Senior VP
Clinical Research Division
Fred Hutch Cancer Center
Seattle, WA
SPEAKING FACULTY
Aditya Bardia, MD, MPH, FASCO
Professor of Medicine
Geffen School of Medicine at UCLA
Program Director, Breast Medical Oncology
Assistant Chief Translational Research, Division of Hematology-Oncology
Director, Translational Research Integration
UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, CA
PROGRAM DESCRIPTION
This enduring program is focused on the use of HER2-directed antibody-drug conjugates (ADCs) for HER2-positive or HER2-low advanced/metastatic breast cancer. It will offer practical guidance on how to incorporate HER2 testing and HER2-directed ADCs into increasingly complex treatment algorithms. During the program, a leading expert in breast cancer will update you on best practices related to HER2 expression testing, review relevant clinical guidelines and trial findings, and discuss monitoring and management of key treatment-related adverse events in patients receiving a HER2-directed therapy for breast cancer. This interactive program combines didactic instruction with case-based discussions and animations.
TARGET AUDIENCE
This educational activity is intended for community-based medical oncologists and other healthcare providers who care for patients with breast cancer.
LEARNING OBJECTIVES
- Describe the importance of HER2 testing in breast cancer patients and the impact of HER2 expression levels on treatment strategies
- Analyze the influence of recent clinical trial findings on treatment recommendations for patients with HER2-positive and HER2-low breast cancer
- Evaluate the potential adverse effects linked to HER2-directed antibody-drug conjugates in patients with advanced or metastatic breast cancer
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Sara A. Hurvitz, MD | Consulting Fees | Paid to institution: BriaCell, BeiGene, Jazz, Boehringer Ingelheim, Menarini Group, Mersana Thearpeutics, Arvinas |
| Contracted Research | Paid to institution: Ambrx, Amgen, Arvinas, AstraZeneca, Bayer, Celcuity, CytomX, Daiichi-Sankyo, Dantari, Dignitana, Genentech/Roche, G1-Therapeutics, Gilead, Greenwich Life Sciences, GSK, Immunomedics, Eli Lilly, Loxo Oncology, MacroGenics, Novartis, OBI Pharma, Orinove, Orum, Pfizer, PMD, Pieris, PUMA, Radius, Samumed, Sanofi, Seattle Genetics/Seagen, Zymeworks/Jazz | |
| Aditya Bardia, MD | Consulting Fees | Pfizer, Novartis, Genentech, Merck, Menarini, Gilead, Sanofi, AstraZeneca/Daiichi Sankyo, Eli Lilly |
| Contracted Research | Pfizer, Novartis, Genentech, Merck, Menarini Group, Gilead, Sanofi, AstraZeneca/Daiichi Sankyo, Eli Lilly |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Lynnsey Medeiros, RN, has nothing to disclose.
- Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
- Kim Farina, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Marissa Mays-Verman, Senior Program Manager for Med Learning Group has nothing to disclose.
- Alexis Klinger, Associate Program Manager for Med Learning Group has nothing to disclose.
- Marcella Guarino, Program Coordinator for Med Learning Group has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group at [email protected]
RELEASED DATE: December 20, 2024
EXPIRATION DATE: December 20, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
